VCM
XBI icon

Vigilant Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Vigilant Capital Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-240
Closed -$23K – 462
2019
Q4 		$23K Buy
+240
New +$20.8K ﹤0.01% 382

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

Vigilant Capital Management's XBI Position: Q1 2020 in Review

Vigilant Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2020, closing a stake of 240 shares — an estimated $23K sold.

Vigilant Capital Management first reported a position in XBI in Q4 2019 and held it in 1 quarter. The position peaked at $23K in Q4 2019. 458 funds tracked by Wall St. Rank hold XBI as of Q1 2020.

  • Vigilant Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2020 after selling out during the quarter.
  • Vigilant Capital Management sold 240 State Street SPDR S&P Biotech ETF shares in Q1 2020, an estimated $23K.
  • Vigilant Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and held it in 1 quarter.
  • Vigilant Capital Management's State Street SPDR S&P Biotech ETF position peaked at $23K in Q4 2019.
  • 458 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2020.

Based on Vigilant Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.